What is it about?

cAMP plays an important role in the transduction of signalling pathways involved in neuroprotection and immune regulation. Control of the levels of this nucleotide by inhibition of cAMP-specific PDEs such as PDE7 may affect the pathological processes of neuroinflammatory diseases like multiple sclerosis (MS). In the present study, we evaluated the therapeutic potential of the selective PDE7 inhibitor, TC3.6, in a model of primary progressive multiple sclerosis (PPMS), a rare and severe variant of MS.

Featured Image

Why is it important?

Our data concur and support the consideration of TC3.6 as a promising new candidate for MS management, including primary progressive MS, as it has both immunomodulatory and neuroprotective properties.

Perspectives

Development of this small molecule to clinical trials will be the only way to finally assess its therapeutic potential for MS patients.

Dr Jose A Morales-Garcia
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERned)

Read the Original

This page is a summary of: PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis, Bone Marrow Transplantation, July 2015, Wiley,
DOI: 10.1111/bph.13192.
You can read the full text:

Read

Contributors

The following have contributed to this page